Background-Onset of atrial fibrillation (AF) has been linked to changes in autonomic tone, with increasing heart rate (HR) immediately before AF onset in some patients suggesting a possible role of acute increases in sympathetic activity in AF onset. Although losartan therapy and decreasing ECG left ventricular hypertrophy are associated with decreased AF incidence, the relationship of HR changes over time to development of AF has not been examined. Methods and Results-HR was evaluated in 8828 hypertensive patients without AF by history or on baseline ECG in the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. Patients were treated with losartan-or atenolol-based regimens and followed with serial ECGs annually which were used to determine HR and ECG left ventricular hypertrophy by Cornell product and Sokolow-Lyon voltage criteria. During mean follow-up of 4.7Ϯ1.1 years, new-onset AF occurred in 701 patients (7.9%). Patients with new AF had smaller decreases in HR to last in-treatment ECG or last ECG before AF (Ϫ2.7Ϯ13.5 versus Ϫ5.2Ϯ12.5 bpm), whether on losartan-(Ϫ0.4Ϯ13.5 versus Ϫ2.2Ϯ11.7 bpm) or atenolol-based treatment (Ϫ5.3Ϯ12.8 versus Ϫ8.3Ϯ12.6 bpm, all PϽ0.001). In univariate Cox analyses, higher HR on in-treatment ECGs was associated with an increased risk of new-onset AF, with a 15% greater risk of AF for every 10 bpm higher HR (95% CI 8% to 22%). In alternative analyses, persistence or development of a HRՆ84 (upper quintile of baseline HR) was associated with a 46% greater risk of developing AF (95% CI 19% to 80%). After adjusting for treatment with losartan versus atenolol, baseline risk factors for AF, baseline and in-treatment systolic and diastolic pressure and the known predictive value of baseline and in-treatment ECG left ventricular hypertrophy for new AF, higher in-treatment HR remained strongly associated with new AF with a 19% higher risk for every 10 bpm higher HR (95% CI 10% to 28%) or a 61% increased rate of AF in patients with persistence or development of a HRՆ84 (95% CI 27% to 104%, all PϽ0.001). 
increased heart rate (HR) may reflect subclinical impairment of LV function, 21 suggest that increasing HR during sinus rhythm may be an important marker of risk for the development of AF. However, the relationship of changing HR over time to the development of new AF has not been evaluated. 22 Accordingly, the present study examined whether higher HR over time is associated with an increased rate of AF in hypertensive patients undergoing treatment, independent of the effects of in-treatment blood pressure and other risk factors for AF, and of the previously demonstrated impact of losartan-based therapy and in-treatment ECG LVH on AF incidence. 3, 23 
Methods

Subjects
The Losartan Intervention for End Point Reduction in Hypertension (LIFE) study 24 -28 enrolled 9193 hypertensive patients with ECG LVH by Cornell voltage-duration product 29, 30 or Sokolow-Lyon voltage criteria 31 on a screening ECG in a prospective, double-blind, randomized study that compared cardiovascular morbidity and mortality with the use of losartan-as opposed to atenolol-based treatment, 26 as previously described in detail. 24 -28 A total of 362 patients with either a history of AF (nϭ342) or AF on their LIFE baseline ECG (nϭ135) and 3 patients with missing baseline HR data were excluded from analyses, leaving 8828 patients without AF by history or baseline ECG in the present study.
Treatment Regimens
Blinded treatment was begun with losartan 50 mg or atenolol 50 mg daily and matching placebo of the other agent, with a target pressure of 140/90 mm Hg or lower. During clinic visits at frequent intervals for the first 6 months and at 6-month intervals thereafter, study therapy could be up-titrated by addition of hydrochlorothiazide 12.5 mg, followed by increase in blinded losartan or atenolol to 100 mg daily. In patients whose blood pressure was still not controlled, additional open-label upward titration of hydrochlorothiazide and if necessary institution of therapy with a calcium channel blocker or additional other medications (excluding AT1-or ␤-blockers or angiotensin-converting enzyme inhibitors) was added to the doubleblind treatment regimen. 26 
Electrocardiography
Study ECGs were obtained at baseline, at 6 months, and at yearly follow-up intervals until study termination or patient death and were interpreted as previously reported in detail. 24 -27 Cornell product Ͼ2440 mm⅐ms 29, 20 or Sokolow-Lyon voltage Ͼ38 mm 31 were used to identify LVH. 24, 25 HR was measured to the nearest bpm on each protocol-mandated study ECG. New-onset AF was identified from protocol-mandated in-study ECGs undergoing Minnesota coding at the ECG core laboratory and/or by adverse event reports of AF by the investigators. 3, 23 
Statistical Analyses
Data management and analyses were performed by the investigators using SPSS version 12.0. Data are presented as meanϮSD for continuous variables and proportions for categorical variables. Differences in mean values between patients grouped according to baseline HR partitioned at 84 bpm (the upper quintile of baseline HR in this population and a value previously shown to stratify mortality risk 32 ) were compared using unpaired t tests; comparison of proportions between groups was performed using 2 tests. The relation of HR during sinus rhythm on baseline and in-study ECGs to risk of developing AF was assessed using Cox proportional hazards models. Baseline risk factors, a treatment group indicator, and baseline HR, systolic and diastolic pressure, Cornell product, and Sokolow-Lyon voltage were included as standard covariates and subsequent in-treatment blood pressure, HR, Cornell product, and Sokolow-Lyon voltage measurements from routine in-study ECGs were entered as time-varying covariates. In addition, the relation of persistence or development of a HRՆ84 versus a HRϽ84 bpm treated as a dichotomous time-varying variable to the development of AF was also analyzed. Treating HR as a time-varying covariate, HR from the last ECG in sinus rhythm before the development of AF or from the last in-treatment ECG will enter into the model. Hazard ratios for incidence of AF associated with in-treatment HR treated as a continuous variable were computed per 10 bpm higher HR values. Analyses were repeated stratifying the population by relevant subgroups by adding cross-product terms of time-varying HR and these subgroup variables into models in the total population.
To illustrate the results of time-varying covariate analyses, new AF rate over time was plotted as a function of changing presence or absence of a HRՆ84 bpm using a univariate modified Kaplan-Meier method, 33 implemented in SAS Release 8.2 on the WIN_PRO platform. Two-tailed PϽ0.05 was required for statistical significance.
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Results
Patient Characteristics in Relation to Baseline HR
Clinical and demographic characteristics of patients in relationship to baseline HR partitioned at 84 bpm are shown in Table 1 . Hypertensive patients with a baseline HRՆ84 were older, more likely to be female, non-black, have diabetes, a history of heart failure, and to be current smokers, had higher body mass indexes, glucose, and total cholesterol levels, and greater albuminuria, but were similar with respect to treatment randomization and other baseline characteristics. Among patients with baseline HRϽ84, compared with those whose HR remained Ͻ84 throughout the study, patients who went on to develop a HRՆ84 before the development of AF or before last follow-up if remaining in sinus rhythm (nϭ555) had similar differences in baseline characteristics as noted in Table 1 with the exception that patients who developed a HRՆ84 were more likely to be black (9.4% versus 5.8%, Pϭ0.002) and to have taken losartan (65.9% versus 49.2%, PϽ0.001), but had similar total cholesterol levels (6.09Ϯ1.09 versus 6.03Ϯ1.11 mmol/L, Pϭ0.200). Blood pressure and ECG LVH measurements at baseline and changes in these measurements between baseline and last in-study determination or the development of new-onset AF in relation to HR at baseline are shown in Table 2 . Patients with a baseline HRՆ84 had slightly higher baseline systolic and diastolic pressures and greater reductions in diastolic pressure but similar changes in systolic pressure. Higher baseline HR was associated with less severe LVH by Sokolow-Lyon voltage, but similar baseline severity of Cornell product LVH and similar changes in both ECG LVH criteria. In-treatment blood pressure control was not related to the behavior of HR during the study: reduction in both systolic and diastolic pressure was similar in patients with persistence or development of a new HRՆ84 and in patients with a HRϽ84 at last follow-up, both among patients who remained in sinus rhythm (Ϫ29Ϯ20 versus Ϫ29Ϯ19 mm Hg, Pϭ0.956 and Ϫ17Ϯ11 versus Ϫ17Ϯ10 mm Hg, Pϭ0.221) and among patients who developed AF (Ϫ33Ϯ19 versus Ϫ34Ϯ21 mm Hg, Pϭ0.766 and Ϫ16Ϯ13 versus Ϫ17Ϯ10 mm Hg, Pϭ0.216).
In-Treatment HR and New AF
During mean follow-up of 4.7Ϯ1.1 years, new-onset AF occurred in 701 patients (7.9%). Compared with patients who did not develop AF, patients who developed AF had smaller decreases in HR to last in-treatment ECG or last ECG before AF (Ϫ2.7Ϯ13.5 versus Ϫ5.2Ϯ12.5), whether on losartan-(Ϫ0.4Ϯ13.5 versus Ϫ2.2Ϯ11.7 bpm) or atenolol-based treatment (Ϫ5.3Ϯ12.8 versus Ϫ8.3Ϯ12.6, all PϽ0.001). Mean time from the last ECG in sinus rhythm to development of new AF was 156Ϯ117 days, with a mean HR of 70Ϯ13 bpm. New-onset AF occurred in 100 patients with in-treatment persistence or development of a HRՆ84 bpm, a rate of 21.1 per 1000 patient-years, and in 601 patients with in-treatment development or continued presence of a HRϽ84 bpm, a rate of 16.4 per 1000 patient-years.
The relationship of new-onset AF to in-treatment HR is examined in Table 3 and in the Figure. In univariate Cox analyses in which time-varying HR was treated as a continuous variable, higher in-treatment values of HR were strongly associated with an increased risk of developing AF: a 10-bpm higher HR was associated with a 15% increased risk of new AF. In parallel analyses in which in-treatment HR was treated as a dichotomous variable based on a threshold value of Ն84 bpm, in-treatment persistence or development of a HRՆ84 *New-onset atrial fibrillation occurred in 601 patients with in-treatment decrease to or continued absence of a heart rate Ն84 bpm for a rate of 15.8 per 1000 patient-years and in 100 patients with in-treatment persistence or development of a heart rate Ն84 bpm for a rate of 20.2 per 1000 patient years.
†Adjusted for possible effects of treatment with losartan vs atenolol, age, gender, race, prevalent diabetes, history of ischemic heart disease, myocardial infarction, congestive heart failure, stroke, peripheral vascular disease or smoking, baseline albumin/creatinine ratio, total and HDL cholesterol, serum creatinine, body mass index, for baseline and in-treatment systolic and diastolic blood pressure, and for baseline and in-treatment Sokolow-Lyon voltage and Cornell voltage-duration product.
bpm was associated with a 46% greater risk of developing AF compared with in-treatment development or continued presence of a HRϽ84. Modified Kaplan-Meier curves 33 comparing the rate of new AF according to a HR of 84 bpm over the time course of the study (Figure) demonstrate that persistence or development of a HRՆ84 was associated with a greater risk of developing AF when compared with a HR Ͻ84, with persistence or development of a HRՆ84 associated with an estimated 6.0% higher absolute incidence of AF after 4 years of follow-up. The predictive value of time-varying HR for new AF was not dependent on whether AF was ascertained on annual study ECG or by adverse clinical event with associated AF: higher in-treatment HR by 10 bpm was similarly predictive of increased incidence of AF defined by annual ECGs (nϭ405, HR 1.25, 95% CI 1.15 to 1.34) or by adverse event reports (nϭ572, HR 1.16, 95% CI 1.08 to 1.24).
The relation of new-onset AF to in-treatment HR was further examined after adjusting for the possible effects of treatment, age, gender, race, prevalent diabetes, history of ischemic heart disease, myocardial infarction, heart failure, stroke, peripheral vascular disease and smoking, baseline urinary albumin/creatinine ratio, total and high-density lipoprotein cholesterol, serum creatinine, body mass index, and for baseline and in-treatment systolic and diastolic blood pressure, Cornell product, and Sokolow-Lyon voltage (Table  3) . After adjusting for these factors, a 10 bpm higher in-treatment HR was associated with a 19% greater risk of new AF; in a parallel analysis, in-treatment persistence or development of a HRՆ84 was associated with a 61% higher incidence of AF. Of note, further adjusting for use of calcium channel blockers treated as a time-varying covariate did not affect the relationship between in-treatment HR and new AF.
The predictive value of time-varying HR for new-onset AF in relevant subsets of the population is examined in Table 4 . The association between new-onset AF and in-treatment HR was similar in men and women, both treatment arms of the study, patients above and below 65 years of age, patients with and without diabetes or a history of ischemic heart disease, myocardial infarction, or heart failure, and patients with and without Cornell product LVH on their baseline ECGs. Higher in-treatment HR was associated with trends toward a greater increase in AF among black as opposed to non-black patients and in patients without as opposed to with LVH by SokolowLyon voltage on their baseline ECGs.
Discussion
These findings demonstrate that higher HR, in sinus rhythm during antihypertensive therapy, is associated with a greater likelihood of new-onset AF, independent of blood pressure lowering, the beneficial effect of losartan-based therapy on the development of AF, 3 and of the previously demonstrated relationship of AF incidence to in-treatment ECG LVH. 23 These findings suggest that serial assessment of HR may provide additional information regarding the risk of developing AF in hypertensive patients and that further evaluation of patients with persistence or development of an increased HR during antihypertensive therapy should be considered to evaluate possible underlying abnormalities that may predispose patients to the development of AF.
HR and AF
The relationship of HR during sinus rhythm to the risk of developing AF has not been well characterized. Among 2576 subjects in the Framingham Heart Study followed for a mean of 10.5 years, 34 baseline HR was similar in the 132 patients who developed AF and the 2444 who remained in sinus rhythm (75Ϯ11 versus 73Ϯ10), but HR over time was not reported in these patients. Among patients with heart failure who were in sinus rhythm, Pozzoli et al 22 found that 18 patients who developed chronic AF had an increase in HR from 72Ϯ16 to 75Ϯ13 bpm between baseline and last evaluation in sinus rhythm when compared with a decrease in HR from 75Ϯ13 to 73Ϯ13 over the same period in 290 patients who remained in sinus rhythm, but did not test the statistical significance of these changes. In contrast, the current study demonstrates that hypertensive patients who developed AF had smaller decreases in HR during losartanor atenolol-based treatment than patients who remained in sinus rhythm and that higher in-treatment HR was strongly associated with an increased risk of developing AF, independent of the beneficial effect of losartan therapy on AF incidence, 3 other potential AF risk factors, and of the previ- Figure. Survival curves illustrating the rate of new onset atrial fibrillation (AF) according to timevarying persistence or development of a heart rate (HR)Ն84 bpm during follow-up. Patient group assignment is adjusted at the time of each ECG based on the heart rate at each time. 33 ously demonstrated relationship of AF incidence to LVH regression in this population. 23 The similar reductions in systolic and diastolic pressure among patients with and without a HRՆ84 and continued strong association of higher in-treatment HR with increased risk of AF after adjusting for in-treatment systolic and diastolic pressure (Table 4) , demonstrate that the association between HR and AF risk was not a marker of lesser blood pressure control among patients with higher in-treatment HR. Importantly, the association between in-treatment HR and new-onset AF was robust across all subsets of the population (Table 4) , including similar effects in patients taking losartan or atenolol despite the different HR responses to therapy in these groups, and among patients with and without a history of heart failure despite the strong association of heart failure with subsequent AF. [3] [4] [5] [6] [7] [8] [9] [10] Possible mechanisms by which increased HR may relate to an increased risk of AF include as a marker of increased sympathetic activity [15] [16] [17] [18] [19] [20] 34 and of subclinical reductions in LV function. 21 The role of the sympathetic nervous system in triggering and maintenance of AF has been more extensively examined, [15] [16] [17] [18] [19] [20] 34 although most studies have focused only on short-term variations in HR variability preceding the development of AF. [15] [16] [17] [18] [19] [20] 34 Increased sympathetic activity may promote automaticity, shorten atrial effective refractory period, and thereby facilitate induction of AF, particularly in patients with structural heart disease. 15 Tachycardia per se can shorten atrial effective refractory period, potentially facilitating AF initiation and propagation. 14, 15, 35 Subclinical LV dysfunction or early heart failure as a cause for increasing HR over time may also impact directly on the risk of 
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developing AF 3-10 via increases in left atrial pressure and stretch that can promote AF. 9,36 -38 Experimental heart failure induced by rapid ventricular pacing promoted the induction of sustained AF in dogs by causing atrial interstitial fibrosis and cellular electrophysiological remodeling distinct from that produced by atrial tachycardia. 39, 40 Study of the relationship of changing HR over time to changes in LV structure and function and left atrial size will be necessary to clarify this relationship.
Methodologic Issues and Study Limitations
Several limitations of the present study warrant review. Use of ECG LVH criteria to select patients for LIFE increased the baseline risk of the study population, suggesting that caution should be used in generalizing these findings to hypertensive patients at lower risk. Although the present findings may not be representative of hypertensive populations with less severe disease, it has been estimated that 7.8 million patients would have met LIFE eligibility criteria in the first 15 member nations of the European Union, 41 with similar numbers in the rest of Europe and in the United States. Second, although annual ECGs and adverse event reports by treating LIFE investigators were used to detect AF, the true incidence of AF, particularly asymptomatic AF, may have been underestimated, potentially reducing precision of the estimates of the relation of AF to in-treatment HR. Third, higher HR was associated with a greater burden of preexisting heart and vascular disease and of risk factors for adverse outcome. Although increased HR remained a strong predictor of new AF after adjusting for these potential confounders, multivariable analyses may not fully take into account the possible impact of these and other unmeasured confounders on outcomes. Fourth, sampling of HR annually on 12-lead ECG almost certainly underestimates the true relationship of changing HR over time to incident AF, which might have been improved by examining 24-hour mean HR or measures of HR variability on serial 24-hour ECGs performed over time. Finally, this was a post hoc analysis of findings from the LIFE study and, as such, further study will be necessary to explore and confirm the relationship of incident AF to changing HR over time.
Implications
These findings have potential implications for the management of patients with hypertension and LVH. Given the increasing incidence and prevalence of AF in the population 1 and the increased risk of death, stroke, and heart failure associated with AF in LIFE and other studies, [3] [4] [5] [6] [7] these data support the serial evaluation of HR in hypertensive patients to monitor the risk of developing AF. These observations suggest that further evaluation of patients with persistence or development of an increased HR during antihypertensive therapy should be considered to evaluate possible underlying abnormalities that may predispose patients to the development of AF. Further study will be required to determine the relationship between increasing HR and structural abnormalities of left atrial size and LV size and function that may predispose to the development of AF. 
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